Merck Stock Worth Watching on PAH Drug Winrevair's Approval in Europe?
https://www.zacks.com/stock/news/2327685/merck-stock-worth-watching-on-pah-drug-winrevair-s-approval-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2327685
Aug 27, 2024 - MRK's Winrevair becomes the first novel activin signaling inhibitor therapy approved in Europe to treat PAH.
0
Top Analyst Reports for Costco, Merck & Linde
https://www.zacks.com/commentary/2326101/top-analyst-reports-for-costco-merck-linde?cid=CS-ZC-FT-research_daily-2326101
Aug 23, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), Merck & Co., Inc. (MRK) and Linde plc (LIN), as well as two micro-cap stocks Hamilton Beach Brands Holding Company (HBB) and Armanino Foods of Distinction, Inc. (AMNF).
0
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
https://www.zacks.com/stock/news/2323310/fda-expands-astrazeneca-s-azn-imfinzi-label-in-lung-cancer?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2323310
Aug 16, 2024 - This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
0
Pharma Stock Roundup: AZN Gets Approvals for Imfinzi Expanded Use, MRK Inks New Deal
https://www.zacks.com/stock/news/2323142/pharma-stock-roundup-azn-gets-approvals-for-imfinzi-expanded-use-mrk-inks-new-deal?cid=CS-ZC-FT-analyst_blog|stock_roundup-2323142
Aug 16, 2024 - Merck (MRK) signs a new collaboration with a private drugmaker. AstraZeneca (AZN) gets approvals for expanded use of Imfinzi.
0
2 Dow Jones Stocks to Buy Hand Over Fist Right Now
https://www.fool.com/investing/2024/08/15/2-dow-jones-stocks-to-buy-hand-over-fist-right-now/?source=iedfolrf0000001
Aug 15, 2024 - Despite a possible recession, these two Dow Jones stocks are still a buy.
0
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
https://www.zacks.com/stock/news/2320865/merck-mrk-to-buy-curon-s-bispecific-antibody-drug-for-1-3b?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2320865
Aug 12, 2024 - Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
0
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
https://www.zacks.com/stock/news/2319903/pharma-stock-roundup-lly-nvo-bayry-q2-earnings-mrk-s-new-deal-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2319903
Aug 09, 2024 - Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
0
Are You Looking for a High-Growth Dividend Stock?
https://www.zacks.com/stock/news/2316248/are-you-looking-for-a-high-growth-dividend-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-2316248
Aug 05, 2024 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
0
Merck (MRK) Q2 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/07/30/merck-mrk-q2-2024-earnings-call-transcript/?source=iedfolrf0000001
Jul 30, 2024 - MRK earnings call for the period ending June 30, 2024.
0
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
https://www.zacks.com/stock/news/2312245/merck-mrk-q2-earnings-sales-beat-estimates-cuts-24-eps-view?cid=CS-ZC-FT-analyst_blog|earnings_article-2312245
Jul 30, 2024 - Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.
0